Compare
LENZ Therapeutics, Inc. vs Pelthos Therapeutics Inc. vs Lineage Cell Therapeutics, Inc. vs Scilex Holding Co
| Latest fiscal year | LENZ Therapeutics, Inc. LENZ | Pelthos Therapeutics Inc. PTHS | Lineage Cell Therapeutics, Inc. LCTX | Scilex Holding Co SCLXRevenue covers only part of its income (partial revenue) |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $19.09M | $16.80M | $14.56M | $30.25M |
| Revenue growth (YoY) | n/a | n/a | +53.2% | -46.5% |
| Gross margin | n/a | 76.3% (computed) | n/a | 65.0% (computed) |
| Operating margin | -477.5% | -193.1% | -251.6% | n/m |
| Net margin | -430.3% | -257.9% | -436.5% | n/m |
| Net income | -$82.13M | -$43.32M | -$63.53M | -$374.05M |
| EPS (Diluted) | -$2.85 | -$23.04 | -$0.28 | -$36.48 |
| Operating cash flow | -$69.17M | -$22.59M | -$18.92M | $3.82M |
| Free cash flow | -$70.00M | -$22.69M | -$19.44M | $3.68M |
| Cash & equivalents | $25.18M | $17.97M | $40.79M | $4.96M |
| Total assets | $305.88M | $130.40M | $112.58M | $364.98M |
| Total liabilities | $21.54M | $91.52M | $69.24M | $576.73M |
| Shareholders' equity | $284.34M | $38.88M | $43.35M | -$207.78M |
| Return on year-end equity | -28.9% | -111.4% | -146.6% | n/a |
| Shares outstanding | 31.34M | 3.23M | 243.12M | 7.03M |
Revenue, most recent five fiscal years
| Fiscal year | LENZ Therapeutics, Inc. | Pelthos Therapeutics Inc. | Lineage Cell Therapeutics, Inc. | Scilex Holding Co |
|---|---|---|---|---|
| Latest | $19.09M Ended 2025-12-31 | $16.80M Ended 2025-12-31 | $14.56M Ended 2025-12-31 | n/a |
| 1 year earlier | $0 Ended 2024-12-31 | $0 Ended 2024-12-31 | $9.50M Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | n/a | $8.95M Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | n/a | $14.70M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | n/a | $4.34M Ended 2021-12-31 | n/a |